ZA200510132B - Glycosaminoglycans for treatment of emotional dysfunctions - Google Patents
Glycosaminoglycans for treatment of emotional dysfunctions Download PDFInfo
- Publication number
- ZA200510132B ZA200510132B ZA200510132A ZA200510132A ZA200510132B ZA 200510132 B ZA200510132 B ZA 200510132B ZA 200510132 A ZA200510132 A ZA 200510132A ZA 200510132 A ZA200510132 A ZA 200510132A ZA 200510132 B ZA200510132 B ZA 200510132B
- Authority
- ZA
- South Africa
- Prior art keywords
- use according
- animals
- day
- pharmaceutical compositions
- glycosaminoglycans
- Prior art date
Links
- 229920002683 Glycosaminoglycan Polymers 0.000 title claims description 23
- 238000011282 treatment Methods 0.000 title claims description 12
- 230000004064 dysfunction Effects 0.000 title claims description 8
- 230000002996 emotional effect Effects 0.000 title claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 7
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 7
- 210000002744 extracellular matrix Anatomy 0.000 claims description 7
- 208000019901 Anxiety disease Diseases 0.000 claims description 6
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 5
- 210000004556 brain Anatomy 0.000 claims description 5
- 229920000669 heparin Polymers 0.000 claims description 5
- 229960002897 heparin Drugs 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 4
- 238000007918 intramuscular administration Methods 0.000 claims description 3
- 238000001990 intravenous administration Methods 0.000 claims description 3
- 238000007920 subcutaneous administration Methods 0.000 claims description 3
- 206010001497 Agitation Diseases 0.000 claims description 2
- 229920001287 Chondroitin sulfate Polymers 0.000 claims description 2
- 208000020401 Depressive disease Diseases 0.000 claims description 2
- 229920000045 Dermatan sulfate Polymers 0.000 claims description 2
- 229920002971 Heparan sulfate Polymers 0.000 claims description 2
- 229920000288 Keratan sulfate Polymers 0.000 claims description 2
- 238000013019 agitation Methods 0.000 claims description 2
- 230000036285 pathological change Effects 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 description 47
- 238000012360 testing method Methods 0.000 description 28
- 230000008014 freezing Effects 0.000 description 15
- 238000007710 freezing Methods 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 230000003750 conditioning effect Effects 0.000 description 9
- 230000006399 behavior Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 6
- 238000012347 Morris Water Maze Methods 0.000 description 5
- 230000006978 adaptation Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000004970 emotional disturbance Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 206010020400 Hostility Diseases 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000015654 memory Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 208000019022 Mood disease Diseases 0.000 description 2
- 206010039897 Sedation Diseases 0.000 description 2
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000001143 conditioned effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000011120 plywood Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 230000036280 sedation Effects 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000006886 spatial memory Effects 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- 206010002942 Apathy Diseases 0.000 description 1
- 206010010305 Confusional state Diseases 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-HNFCZKTMSA-N L-idopyranuronic acid Chemical compound OC1O[C@@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-HNFCZKTMSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 1
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- RMUCZJUITONUFY-UHFFFAOYSA-N Phenelzine Chemical compound NNCCC1=CC=CC=C1 RMUCZJUITONUFY-UHFFFAOYSA-N 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- XJCLWVXTCRQIDI-UHFFFAOYSA-N Sulfallate Chemical compound CCN(CC)C(=S)SCC(Cl)=C XJCLWVXTCRQIDI-UHFFFAOYSA-N 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 description 1
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 1
- 229960002495 buspirone Drugs 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003874 central nervous system depressant Substances 0.000 description 1
- 230000002060 circadian Effects 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 208000004209 confusion Diseases 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000000881 depressing effect Effects 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 150000002016 disaccharides Chemical group 0.000 description 1
- 230000006397 emotional response Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 208000037870 generalized anxiety Diseases 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007074 memory dysfunction Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 230000037023 motor activity Effects 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 229960000964 phenelzine Drugs 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 1
- 210000004894 snout Anatomy 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000033912 thigmotaxis Effects 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 229960000604 valproic acid Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT001023A ITMI20031023A1 (it) | 2003-05-21 | 2003-05-21 | Glicosaminoglicani aventi peso molecolare medio 2400 d atti al trattamento delle disfunzioni emozionali. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200510132B true ZA200510132B (en) | 2006-08-30 |
Family
ID=30131059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200510132A ZA200510132B (en) | 2003-05-21 | 2005-12-13 | Glycosaminoglycans for treatment of emotional dysfunctions |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US7812005B2 (no) |
| EP (1) | EP1631298B8 (no) |
| JP (1) | JP4757197B2 (no) |
| KR (1) | KR20060025142A (no) |
| CN (1) | CN100377717C (no) |
| AT (1) | ATE373480T1 (no) |
| AU (1) | AU2004241748B2 (no) |
| CA (1) | CA2526201A1 (no) |
| DE (1) | DE602004009068T2 (no) |
| DK (1) | DK1631298T3 (no) |
| ES (1) | ES2294507T3 (no) |
| HK (1) | HK1084023A1 (no) |
| IL (1) | IL171981A (no) |
| IT (1) | ITMI20031023A1 (no) |
| NO (1) | NO20056089L (no) |
| NZ (1) | NZ544238A (no) |
| PL (1) | PL1631298T3 (no) |
| PT (1) | PT1631298E (no) |
| RU (1) | RU2353371C2 (no) |
| WO (1) | WO2004103381A1 (no) |
| ZA (1) | ZA200510132B (no) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101584704B (zh) * | 2008-05-23 | 2010-12-15 | 鲁南制药集团股份有限公司 | 肝素、低分子肝素可药用盐或其衍生物的医药用途 |
| CN107760713B (zh) * | 2016-08-23 | 2020-05-05 | 中国科学院上海药物研究所 | 一种非人哺乳动物神经精神疾病动物模型的建立方法及其用途 |
| CN112438991B (zh) * | 2019-08-29 | 2024-03-15 | 鲁南制药集团股份有限公司 | 肝素、或其衍生物、或其可药用盐的医药用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4351938A (en) * | 1980-05-19 | 1982-09-28 | Riker Laboratories, Inc. | Anticoagulant substance |
| US4916219A (en) * | 1985-03-28 | 1990-04-10 | University Of Iowa Research Foundation | Oligosaccharide heparin fragments as inhibitors of complement cascade |
| IT1205042B (it) | 1987-05-28 | 1989-03-10 | Crinos Industria Farmaco | Composizione farmaceutica ad attivita' terapeutica per il trattamento della demenza senile di tipo alzheimer |
| US5605938A (en) | 1991-05-31 | 1997-02-25 | Gliatech, Inc. | Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate |
| FR2763848B1 (fr) * | 1997-05-28 | 2000-01-28 | Rhone Poulenc Rorer Sa | Utilisation des heparines de bas poids moleculaire pour la prevention et le traitement du trauma du systeme nerveux central |
| FR2763849B1 (fr) * | 1997-05-28 | 2000-09-15 | Rhone Poulenc Rorer Sa | Utilisation des heparines de bas poids moleculaire pour la prevention et le traitement des oedemes cerebraux |
| JP4412756B2 (ja) * | 1998-02-26 | 2010-02-10 | 生化学工業株式会社 | 新規多糖誘導体、その製造法及びそれを有効成分とする医薬組成物 |
| IT1312107B1 (it) * | 1999-05-14 | 2002-04-04 | Umberto Cornelli | Glicosaminoglicani aventi peso molecolare medio di 2400 d atti altrattamento della demenza senile |
-
2003
- 2003-05-21 IT IT001023A patent/ITMI20031023A1/it unknown
-
2004
- 2004-05-19 ES ES04741606T patent/ES2294507T3/es not_active Expired - Lifetime
- 2004-05-19 WO PCT/EP2004/050860 patent/WO2004103381A1/en active IP Right Grant
- 2004-05-19 AT AT04741606T patent/ATE373480T1/de not_active IP Right Cessation
- 2004-05-19 AU AU2004241748A patent/AU2004241748B2/en not_active Expired - Fee Related
- 2004-05-19 JP JP2006530208A patent/JP4757197B2/ja not_active Expired - Fee Related
- 2004-05-19 DK DK04741606T patent/DK1631298T3/da active
- 2004-05-19 NZ NZ544238A patent/NZ544238A/en unknown
- 2004-05-19 DE DE602004009068T patent/DE602004009068T2/de not_active Expired - Fee Related
- 2004-05-19 EP EP04741606A patent/EP1631298B8/en not_active Expired - Lifetime
- 2004-05-19 PL PL04741606T patent/PL1631298T3/pl unknown
- 2004-05-19 KR KR1020057021781A patent/KR20060025142A/ko not_active Application Discontinuation
- 2004-05-19 CA CA002526201A patent/CA2526201A1/en not_active Abandoned
- 2004-05-19 US US10/557,860 patent/US7812005B2/en not_active Expired - Fee Related
- 2004-05-19 RU RU2005138517/15A patent/RU2353371C2/ru not_active IP Right Cessation
- 2004-05-19 PT PT04741606T patent/PT1631298E/pt unknown
- 2004-05-19 CN CNB2004800136097A patent/CN100377717C/zh not_active Expired - Fee Related
-
2005
- 2005-11-15 IL IL171981A patent/IL171981A/en not_active IP Right Cessation
- 2005-12-13 ZA ZA200510132A patent/ZA200510132B/en unknown
- 2005-12-21 NO NO20056089A patent/NO20056089L/no not_active Application Discontinuation
-
2006
- 2006-04-07 HK HK06104250A patent/HK1084023A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1631298A1 (en) | 2006-03-08 |
| IL171981A (en) | 2010-04-15 |
| PT1631298E (pt) | 2007-12-31 |
| DE602004009068D1 (de) | 2007-10-31 |
| AU2004241748A1 (en) | 2004-12-02 |
| AU2004241748B2 (en) | 2010-05-13 |
| JP2006528670A (ja) | 2006-12-21 |
| WO2004103381A1 (en) | 2004-12-02 |
| NO20056089L (no) | 2006-02-09 |
| KR20060025142A (ko) | 2006-03-20 |
| EP1631298B8 (en) | 2008-12-24 |
| IL171981A0 (en) | 2006-04-10 |
| EP1631298B1 (en) | 2007-09-19 |
| US7812005B2 (en) | 2010-10-12 |
| CN100377717C (zh) | 2008-04-02 |
| JP4757197B2 (ja) | 2011-08-24 |
| DK1631298T3 (da) | 2008-01-28 |
| RU2353371C2 (ru) | 2009-04-27 |
| DE602004009068T2 (de) | 2008-06-19 |
| HK1084023A1 (en) | 2006-07-21 |
| ATE373480T1 (de) | 2007-10-15 |
| ITMI20031023A1 (it) | 2004-11-22 |
| PL1631298T3 (pl) | 2008-04-30 |
| ITMI20031023A0 (it) | 2003-05-21 |
| CA2526201A1 (en) | 2004-12-02 |
| RU2005138517A (ru) | 2006-08-27 |
| US20060205690A1 (en) | 2006-09-14 |
| CN1791416A (zh) | 2006-06-21 |
| NZ544238A (en) | 2008-08-29 |
| ES2294507T3 (es) | 2008-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pytko-Polonczyk et al. | Artificial saliva and its use in biological experiments | |
| AU2021204465B2 (en) | Extended release pharmaceutical compositions of levetiracetam | |
| JP2011523934A (ja) | 骨関節疾患の治療又は予防において使用するための医薬組成物 | |
| ITTO20080804A1 (it) | Composizione iniettabile di polinucleotidi per il trattamento di patologie osteoarticolari. | |
| RU2709814C1 (ru) | Применение альгинатных олигомеров в качестве антикоагулянтов крови | |
| Jakovljević et al. | Seasonal influence on platelet 5-HT levels in patients with recurrent major depression and schizophrenia | |
| CN1794999B (zh) | 神经损伤治疗剂 | |
| ZA200510132B (en) | Glycosaminoglycans for treatment of emotional dysfunctions | |
| BR112012003149B1 (pt) | composição farmacêutica para alívio de dor em uma doença de junta humana | |
| AU2010212350A1 (en) | Mixture of hyaluronic acid for treating and preventing inflammatory bowel disease | |
| KR20010071572A (ko) | 발프로산 유사체를 편두통 및 기분 장애의 치료 및 예방에사용하는 용도 | |
| WO2019246264A1 (en) | Cell protective methods and compositions | |
| ES2404819T3 (es) | Aplicación de 3,5-dihidroxitolueno o derivados de este en la preparación de medicina y alimento funcional para tratar o prevenir la depresión | |
| HU206614B (en) | Process for producing antianxiative pharmaceutical compositions containing angiotenzin-converting anzyme inhibitor | |
| EP2090308A1 (en) | Pharmaceutical composition for the treatment or prevention of osteoarticular diseases | |
| US20060179492A1 (en) | Method of inhibiting neural transmission mediated by serotonin-2a and enhancing sensorimotor gating | |
| JP2015038047A (ja) | Ｓｉｒｔ３誘導剤 | |
| Carraro | Translational Myology for Impaired Mobility | |
| DENTYSTYCZNE | THE RELATIONSHIP BETWEEN COLONIZATION RESISTANCE OF THE ORAL CAVITY AND INDIVIDUAL-TYPOLOGICAL CHARACTERISTICS OF PERSONALITY: DENTAL ASPECTS ZWIĄZEK POMIĘDZY OPORNOŚCIĄ KOLONIZACYJNĄ MIKROORGANI-ZMÓW JAMY USTNEJ A INDYWIDUALNĄ TYPOLOGICZNĄ CHARAKTE | |
| OA18467A (en) | Extended release pharmaceutical compositions of levetiracetam | |
| McBroom et al. | The effectiveness of oral suppression in high risk prosthetic joint infections after total knee arthroplasty | |
| UA118389U (uk) | Спосіб комплексного лікування хворих на генералізований пародонтит | |
| UA48667A (uk) | Спосіб лікування дифтерії |